About us
Redx is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease
Our pipelineTargeting Fibrosis
Fibrosis is an internal scarring process, which can occur in response to injury, where excess connective tissue is deposited in an organ or tissue – thereby impairing its function. Most chronic inflammatory diseases will result in fibrosis, with progressive injury resulting in organ failure. Fibrotic disease can occur in nearly any tissue in the body and contributes to 35% of deaths in the developed world.1,2 Solid organ (such as lung, liver or kidney) fibrosis can occur as a result of many different diseases and underlying health issues, including obesity or diabetes. Current therapeutic options are limited for these chronic and often life-threatening diseases.
We leverage the anti-fibrotic potential of the ROCK (Rho-associated coiled-coil protein kinase) pathway with our ROCK inhibitor portfolio. RXC008 is a potential first-in-class GI-restricted pan ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, which has successfully completed a Phase 1 healthy volunteer study and is preparing to commence a Phase 2 study.
Zelasudil (RXC007) is a next-generation selective ROCK2 inhibitor, with potential in multiple interstitial lung diseases and other fibrotic indications including MASH and cancer-associated fibrosis, which has recently completed a signal searching Phase 2 clinical programme in idiopathic pulmonary fibrosis (IPF) patients.
In addition to our focus on the ROCK pathway in fibrosis, we have an extensive programme of pre-clinical research focused on the novel target, Discoidin Domain Receptors (DDRs). DDR expression is increased in many fibrotic diseases and preclinical proof-of-concept for small molecule inhibitors has been demonstrated in models of lung and kidney fibrosis.
Beyond fibrosis we have a pipeline of differentiated oncology programmes and collaborations, including our clinical stage oncology asset, zamaporvint (RXC004), which is in Phase 2 clinical development for patients with Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy.
Our core strengths in medicinal chemistry, translational science and clinical development have enabled us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets. These strengths have been recognised by others, and we have successfully completed a number of partnering deals in recent years including with AstraZeneca, (Porcupine inhibitor, AZD5055 previously RXC006), Loxo Oncology ( FDA approved BTK inhibitor, JaypircaTM, pirtobrutinib/LOXO-305, previously RXC005), and two programmes with Jazz Pharmaceuticals (phase 1 Pan-RAF inhibitor, JZP815, and a pan-KRAS Inhibitor programme RXC010).
References
- Rieder, F., Nagy, L.E., Maher, T.M. et al. Nat Rev Drug Discov (2025).
- Mutsaers, H.A.M., Merrild, C., Nørregaard, R. et al. J Transl Med 21, 818 (2023).
Pioneering the Next Generation of Anti-Fibrotic Medicines
Our core strengths in medicinal chemistry and translational science have enabled us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is an opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need. We have built an attractive portfolio of assets and have a strong track record of drug discovery having delivered six molecules to clinical stage development.
Our strategic focus is on advancing our differentiated lead asset, RXC008, a potential first-in-class GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease and building our programme targeting DDR, a novel fibrosis target.
GI-restricted pan-ROCK Inhibitor
(RXC008)
RXC008 is a clinical stage, orally active GI-restricted pan-ROCK (ROCK1/2) inhibitor being developed for the treatment of fibrostenotic Crohn’s disease.
We have earmarked key programmes in our pipeline for partnership including zelasudil (RXC007), a next-generation, selective ROCK2 inhibitor for the treatment of interstitial lung diseases and multiple fibrotic diseases and zamaporvint (RXC004), a clinical stage Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy.
ROCK2 Selective Inhibitor
Zelasudil (RXC007)
Zelasudil is a clinical stage, highly selective and orally available ROCK2 inhibitor being developed for the treatment of interstitial lung diseases and other fibrotic indications.
Our values
At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.
Our core strengths in medicinal chemistry and translational science enable us to develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class drug candidates for diseases of unmet medical need.
Our five core company values underpin everything we do.
High Standards
We stand or fall by quality data
Resilience
We can’t win by giving up
Teamwork
Together we are stronger
Innovation
Bright ideas fuel our pipeline
Agility
The market waits for no-one